Clinical Policy: Pancreas Transplantation

This policy describes the medical necessity requirements for pancreas transplantation procedures. Multiple types of pancreas transplants are effective therapeutic options for arresting the progression of the complications of diabetes mellitus, and improving the quality of life for diabetic patients, including: simultaneous pancreas kidney transplant (SPK), pancreas after kidney transplant (PAK), pancreas transplant alone (PTA), and islet cell transplant. The SPK procedure is most commonly performed transplant procedure, and has the highest post-operative graft survival rates.

Policy/Criteria

I. It is the policy of health plans affiliated with Centene Corporation® that a pancreas transplant is medically necessary when meeting all of the following:
   A. Medical therapy for condition does not exist or has failed;
   B. Diagnosis of diabetes mellitus, as demonstrated by one of the following:
      1. Dependent on insulin and C-peptide value ≤ 2 ng/mL;
      2. Dependent on insulin and C-peptide value ≥ 2 ng/mL and BMI ≤ maximal allowable value;
   C. Does not have ANY of the following contraindications:
      1. Malignancy in the past two years, except for either of the following:
         a. Non-melanoma localized skin cancer that has been treated appropriately;
         b. Early prostate cancer with a low Gleason score;
      2. Malignancy metastasized to or extending beyond the margins of the kidney and/or pancreas;
      3. Untreatable significant dysfunction of another major organ system, unless combined organ transplantation can be performed;
      4. Acute medical instability, including, but not limited to, acute sepsis or myocardial infarction;
      5. Uncorrectable bleeding diathesis;
      6. Chronic infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant;
      7. Current non-adherence to medical therapy or a history of repeated or prolonged episodes of non-adherence to medical therapy that are perceived to increase the risk of non-adherence after transplantation;
      8. Psychiatric or psychological condition associated with the inability to cooperate or comply with medical therapy;
      9. Absence of an adequate or reliable social support system;
     10. Severely limited functional status with poor rehabilitation potential;
     11. Substance abuse or dependence (including tobacco and alcohol) without convincing evidence of risk reduction behaviors, such as meaningful and/or long-term
participation in therapy for substance abuse and/or dependence. Serial blood and urine testing may be used to verify abstinence from substances that are of concern.

D. Request is for one of the following procedures and meets the corresponding criteria:

1. **PTA**, meets all:
   a. Recurrent, severe, and potentially life-threatening metabolic complications that require medical attention, as documented by chart notes, emergency room visits, or hospitalizations, including any of the following:
      i. Severe hypoglycemia unawareness;
      ii. Marked hyperglycemia;
      iii. Recurring severe ketoacidosis;
   b. Clinical and emotional problems with exogenous insulin therapy that are so severe as to be incapacitating or consistent failure of insulin based management to prevent acute complications;

2. **SPK**, meets all:
   a. End-stage renal disease (ESRD), as defined by both
      i. Presence of uremia;
      ii. Requires dialysis or is expected to require dialysis in the next 12 months;
   b. Glomerular filtration rate (GFR) < 20mL/min or creatinine clearance (CrCl) < 20mL/min;

3. **PAK transplant**, meets all:
   a. Underwent successful kidney transplant without significant chronic rejection of kidney transplant;
   b. Stable kidney transplant function, as defined by both:
      i. Stable creatinine clearance $\geq 30$ mL/min,
      ii. Absence of significant proteinuria.

II. It is the policy of health plans affiliated with Centene Corporation that autologous islet cell transplants are considered medically necessary as an adjunct procedure to a total or near total pancreatectomy for severe, refractory pancreatitis.

III. It is the policy of health plans affiliated with Centene Corporation that pancreas re-transplantation are considered medically necessary after one failed primary pancreas transplant.

IV. It is the policy of health plans affiliated with Centene Corporation that pancreas transplant procedures are considered experimental/investigational for any of the following indications:
   A. Re-transplantations after two or more failed primary pancreas transplantations;
   B. Allogeneic islet cell transplantation or xenotransplantation;
   C. SPK transplantation for patients with amputation due to peripheral obstructive vascular disease;
   D. For the treatment of all other conditions than those specified above.

**Background**

The American Diabetes Association defines diabetes mellitus as a group of metabolic diseases, which is characterized by hyperglycemia that results from defects in insulin secretion, insulin action, or both. According to the Centers for Disease Control and Prevention (CDC)’s
estimations in 2012, approximately 29.1 million people or 9.3% of the U.S. population have diabetes, with an approximate 8.1 million undiagnosed cases.\(^3\) The chronic hyperglycemia existing in diabetic patients facilitates long term organ damage, especially to the eyes, kidneys, nerves, and blood vessels.\(^1\)

The prevalent type 2 diabetes is caused by a resistance to insulin action and an inadequate compensatory insulin secretory response.\(^1\) Type 1 diabetes is caused by immune mediated destruction of the insulin secreting pancreatic β cells.\(^2\) Islet cell autoantibodies, insulin autoantibodies, autoantibodies to glutamic acid decarboxylase, zinc transporter 8 (ZnT8A), and autoantibodies to the tyrosine phosphatase IA-2 and IA-2\(\beta\) are serological markers of the pancreatic β cell destruction observed in type 1 diabetes.\(^1,2,4\)

Due to the loss of glucose homeostasis in diabetes mellitus and the dependency of exogenous insulin for glycemic control, pancreatic transplantations presents options to restore glucose regulated endogenous insulin secretion, arrest the progression of the complications of diabetes, and to improve the quality of life for diabetic patients.\(^5\) In fact, pancreas transplantation is the only proven method to restore normoglycemia in type 1 diabetic patients.

There are multiple iterations of pancreas transplantation procedures available to diabetic patients: simultaneous pancreas kidney transplant (SPK), pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA), as well as islet cell transplantation. SPK, performed for patients with type 1 diabetes with end stage renal disease, is the most common pancreas transplant procedure.\(^6\) A comprehensive analysis of the 35,000 pancreas transplantations reported to the International Pancreas Transplant Registry as of 2010, 75% of the procedures are SPK, 18% are PAK transplant, and 9% are PTA.\(^6\)

Patient survival rates were reported at > 95% at 1 year and > 83% at 5 years.\(^6\) The best graft survival rates were observed in SPK transplants at 86% for pancreas and 93% for kidney at one year; PAK procedures displayed graft function at 80%, while PTA had graft function at 78%.\(^6\) Graft survival rate is defined as total freedom from insulin therapy, normal fasting blood glucose concentrations, and normal or only slightly elevated HbA1c values.\(^8\) Patient survival rates were 95 to 98% at one year, 91 to 92% at 3 years and 78 to 88% at 5 years post operatively.\(^5\) In all three categories, cardio/cerebrovascular problems as well as infections were the leading cause of early and late death.\(^6\)

Patients undergoing the pancreas transplantation, especially the SPK procedure, require extensive immunosuppression regiments; pancreas transplants recipients are believed to require higher levels of immunosuppression than other solid organ transplants, possibly related to the immunogenicity of the pancreas, and or the autoimmune status of the recipients.\(^7\)

Pancreatic islet autotransplantation is performed following a pancreatectomy in patients with severe chronic pancreatitis. Islet β cells transferred into the liver through the portal vein of the recipient.\(^5\) One of the primary symptoms and complications observed in patients with chronic pancreatitis is excessive pain. Therefore control of pain is a primary goal of pancreatectomy and pancreatic islet autotransplantation. Post-operative opiate usage has been reported as an outcome metric for pain relief, and reductions ranging from approximately 20-80% have been reported due to pancreatic islet autotransplantation.\(^8\)
References
5. Robertson, RP. “Pancreas and islet transplantation in diabetes mellitus.” In: UpToDate, Hirsch, IB. Ed. UpToDate, Waltham, MA. (Accessed on January 24 2019

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>48160</td>
<td>Pancreatectomy, total or subtotal, with autologous transplantation of pancreas of pancreatic islet cells</td>
</tr>
<tr>
<td>48550</td>
<td>Donor pancreatectomy (including cold preservation), with or without duodenal segment for transplantation</td>
</tr>
<tr>
<td>48551</td>
<td>Backbench standard preparation of cadaver donor pancreas allograft prior to transplantation, including dissection of allograft from surrounding soft tissues, splenectomy, duodenotomy, ligation of bile duct, ligation of mesenteric vessels, and Y-graft arterial anastomoses from iliac artery to superior mesenteric artery and to splenic artery</td>
</tr>
<tr>
<td>48552</td>
<td>Backbench reconstruction of cadaver donor pancreas allograft prior to transplantation, venous anastomosis, each</td>
</tr>
<tr>
<td>48554</td>
<td>Transplantation of pancreatic allograft</td>
</tr>
<tr>
<td>48556</td>
<td>Removal of transplanted pancreatic allograft</td>
</tr>
<tr>
<td>50300</td>
<td>Donor nephrectomy (including cold preservation) from cadaver donor, unilateral or bilateral</td>
</tr>
<tr>
<td>50320</td>
<td>Donor nephrectomy (including cold preservation); open, from living donor</td>
</tr>
<tr>
<td>50323</td>
<td>Backbench standard preparation of cadaver donor renal allograft prior to transplantation, including dissection and removal of perinephric fat, diaphragmatic and retroperitoneal attachments, excision of adrenal gland, and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary</td>
</tr>
<tr>
<td>50325</td>
<td>Backbench standard preparation of living donor renal allograft (open or laparoscopic) prior to transplantation, including dissection and removal of perinephric fat and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary</td>
</tr>
<tr>
<td>50327</td>
<td>Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; venous anastomosis, each</td>
</tr>
<tr>
<td>50340</td>
<td>Recipient nephrectomy (separate procedure)</td>
</tr>
<tr>
<td>50360</td>
<td>Renal allotransplantation, implantation of graft; without recipient nephrectomy</td>
</tr>
<tr>
<td>50365</td>
<td>Renal allotransplantation, implantation of graft; with recipient nephrectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2065</td>
<td>Simultaneous pancreas kidney transplantation</td>
</tr>
</tbody>
</table>

**ICD-10 Diagnosis Codes that Support Coverage Criteria**

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E10.10-E10.9</td>
<td>Type 1 diabetes mellitus with kidney complications</td>
</tr>
<tr>
<td>K86.0</td>
<td>Alcohol-induced chronic pancreatitis</td>
</tr>
<tr>
<td>K86.1</td>
<td>Other chronic pancreatitis</td>
</tr>
<tr>
<td>N18.4</td>
<td>Chronic kidney disease, stage 4 (severe)</td>
</tr>
<tr>
<td>N18.5</td>
<td>Chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>N18.6</td>
<td>End stage renal disease</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Z94.0</td>
<td>Kidney transplant status</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

- Policy developed. Reviewed by specialist 4/16.  
  Date: 02/16  Approval Date: 04/16
- References reviewed and updated  
  Date: 03/17  Approval Date: 03/17
- Removed “islet cell transplantation” from III. References reviewed and updated. ICD-10 and HCPCS codes added.  
  Date: 01/18  Approval Date: 02/18
- Minor wording changes to description for clarity  
  Date: 05/18
- Added “early prostate cancer with a low Gleason score,” as an exception to malignancy contraindication, I.b. Removed “and/or islet cell” from IV. A. References reviewed and updated. Specialist reviewed.  
  Date: 01/19  Approval Date: 02/19

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCD’s and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.